Skip to main content
Top
Published in: Supportive Care in Cancer 10/2020

01-10-2020 | Brachytherapy | Review Article

A systematic review of the impact of contemporary treatment modalities for cervical cancer on women’s self-reported health-related quality of life

Authors: L. M. Wiltink, M. King, F. Müller, M. S. Sousa, M. Tang, A. Pendlebury, J. Pittman, N. Roberts, L. Mileshkin, R. Mercieca-Bebber, M.-A. Tait, R. Campbell, C. Rutherford

Published in: Supportive Care in Cancer | Issue 10/2020

Login to get access

Abstract

Purpose

Given the high survival rate of cervical cancer patients, understanding women’s health-related quality of life (HRQL) during and after treatment is of major clinical importance. We conducted a systematic review to synthesize all available evidence about the effects of each contemporary treatment modality for cervical cancer on all dimensions of women’s HRQL, including symptoms, functioning, and global HRQL.

Methods

We searched four electronic databases from January 2000 to September 2019, cross-referenced and searched by author name for studies of patients treated for cervical cancer that reported patient-reported outcomes (PROs) before treatment and with at least one post-treatment measurement. Two independent reviewers applied inclusion and quality criteria and extracted findings. Studies were categorized by treatment to determine specific treatment effects on PROs. Results were narratively summarized.

Results

We found twenty-nine papers reporting 23 studies. After treatments with curative intent for early or locally advanced disease, lymphedema, diarrhea, menopausal symptoms, tight and shorter vagina, pain during intercourse, and sexual worries remained long-term problems; however, sexual activity improved over time. HRQL and psychological distress were impacted during treatment with also worsening of global HRQL but improved 3–6 months after treatment. In patients with metastatic or recurrent disease, pain improved during palliative treatment or remained stable, with no differences in global HRQL found over time.

Conclusion

Whereas most symptoms worsen during treatment and improve in the first 3 months after completing treatment, symptoms like lymphedema, menopausal symptoms, and sexual worries develop gradually and persist after curative treatment. These findings can be used to inform clinical practice and facilitate communication and shared decision-making. More research is needed in very early cervical cancer and the impact of fertility sparing therapy on PROs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRef
2.
go back to reference Noone AM, H N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2018) SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site Noone AM, H N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2018) SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://​seer.​cancer.​gov/​csr/​1975_​2015/​, based on November 2017 SEER data submission, posted to the SEER web site
3.
go back to reference Marth C et al (2017) Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 28(suppl_4):iv72–iv83PubMed Marth C et al (2017) Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 28(suppl_4):iv72–iv83PubMed
4.
go back to reference Cohen PA, Jhingran A, Oaknin A, Denny L (2019) Cervical cancer. Lancet 393(10167):169–182PubMed Cohen PA, Jhingran A, Oaknin A, Denny L (2019) Cervical cancer. Lancet 393(10167):169–182PubMed
5.
go back to reference Bhatla N et al (2018) Cancer of the cervix uteri. Int J Gynaecol Obstet 143(Suppl 2):22–36PubMed Bhatla N et al (2018) Cancer of the cervix uteri. Int J Gynaecol Obstet 143(Suppl 2):22–36PubMed
6.
go back to reference Bhatla N et al (2019) Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 145(1):129–135PubMed Bhatla N et al (2019) Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 145(1):129–135PubMed
7.
go back to reference Shimamoto K, Saito T, Kitade S, Tomita Y, Nagayama R, Yamaguchi S, Ariyoshi K, Okadome M (2018) A study of treatments and outcomes in elderly women with cervical cancer. Eur J Obstet Gynecol Reprod Biol 228:174–179PubMed Shimamoto K, Saito T, Kitade S, Tomita Y, Nagayama R, Yamaguchi S, Ariyoshi K, Okadome M (2018) A study of treatments and outcomes in elderly women with cervical cancer. Eur J Obstet Gynecol Reprod Biol 228:174–179PubMed
8.
go back to reference Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12(3):608–616PubMed Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12(3):608–616PubMed
9.
go back to reference Rutherford C, M-B R., Tait M, Mileshkin L, King M (2017) Quality of life in cervical cancer. In: Farghaly S (editor) Uterine cervical cancer: clinical and therapeautic perspectives. Springer, New York. https://doi.org/10.1007/978-3-030-02701-8 [ISBN (Print): 978-3-030-02700-1; ISBN (EBook): 978-3-030-02700-1] Rutherford C, M-B R., Tait M, Mileshkin L, King M (2017) Quality of life in cervical cancer. In: Farghaly S (editor) Uterine cervical cancer: clinical and therapeautic perspectives. Springer, New York. https://​doi.​org/​10.​1007/​978-3-030-02701-8 [ISBN (Print): 978-3-030-02700-1; ISBN (EBook): 978-3-030-02700-1]
10.
go back to reference Food and Drug Administration (2009) Patient reported outcome measures: use in medical product development to support labelling claims. MD: US Department of Health & Human Support Food & Drug Administration Food and Drug Administration (2009) Patient reported outcome measures: use in medical product development to support labelling claims. MD: US Department of Health & Human Support Food & Drug Administration
11.
go back to reference Moher D et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7) Moher D et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7)
12.
go back to reference Kmet LM, Lee RC, Cook LS (2004) Standard quality assessment criteria for evaluating primary research papers froma variety of fields. Alberta Heritage Foundation for Medical Research, Edmonton Kmet LM, Lee RC, Cook LS (2004) Standard quality assessment criteria for evaluating primary research papers froma variety of fields. Alberta Heritage Foundation for Medical Research, Edmonton
13.
go back to reference Calvert MP et al (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309(8):814–822PubMed Calvert MP et al (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309(8):814–822PubMed
14.
go back to reference Bogani G, Serati M, Nappi R, Cromi A, di Naro E, Ghezzi F (2014) Nerve-sparing approach reduces sexual dysfunction in patients undergoing laparoscopic radical hysterectomy. J Sex Med 11(12):3012–3020PubMed Bogani G, Serati M, Nappi R, Cromi A, di Naro E, Ghezzi F (2014) Nerve-sparing approach reduces sexual dysfunction in patients undergoing laparoscopic radical hysterectomy. J Sex Med 11(12):3012–3020PubMed
15.
go back to reference Carter J, Sonoda Y, Baser RE, Raviv L, Chi DS, Barakat RR, Iasonos A, Brown CL, Abu-Rustum NR (2010) A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. Gynecol Oncol 119(2):358–365PubMedPubMedCentral Carter J, Sonoda Y, Baser RE, Raviv L, Chi DS, Barakat RR, Iasonos A, Brown CL, Abu-Rustum NR (2010) A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. Gynecol Oncol 119(2):358–365PubMedPubMedCentral
16.
go back to reference Conic I et al (2012) Anxiety levels related to the type of therapy for cervical cancer. Central Eur J Med 7(4):490–496 Conic I et al (2012) Anxiety levels related to the type of therapy for cervical cancer. Central Eur J Med 7(4):490–496
17.
go back to reference Ding Y, Hu Y, Hallberg IR (2013) Health-related quality of life and associated factors in Chinese women with cervical cancer: a 9-month follow-up. Cancer Nurs 36(4):E18–E26PubMed Ding Y, Hu Y, Hallberg IR (2013) Health-related quality of life and associated factors in Chinese women with cervical cancer: a 9-month follow-up. Cancer Nurs 36(4):E18–E26PubMed
18.
go back to reference Du Toit GC, Kidd M (2015) Prospective quality of life study of south African women undergoing treatment for advanced-stage cervical cancer. Clin Ther 37(10):2324–2331PubMed Du Toit GC, Kidd M (2015) Prospective quality of life study of south African women undergoing treatment for advanced-stage cervical cancer. Clin Ther 37(10):2324–2331PubMed
19.
go back to reference Ferrandina G, Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, Moruzzi C, Lorusso D, Marcellusi A, Scambia G (2012) Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecol Oncol 124(3):389–394PubMed Ferrandina G, Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, Moruzzi C, Lorusso D, Marcellusi A, Scambia G (2012) Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecol Oncol 124(3):389–394PubMed
20.
go back to reference Hawighorst-Knapstein S, Fusshoeller C, Franz C, Trautmann K, Schmidt M, Pilch H, Schoenefuss G, Georg Knapstein P, Koelbl H, Kelleher DK, Vaupel P (2004) The impact of treatment for genital cancer on quality of life and body image - results of a prospective longitudinal 10-year study. Gynecol Oncol 94(2):398–403PubMed Hawighorst-Knapstein S, Fusshoeller C, Franz C, Trautmann K, Schmidt M, Pilch H, Schoenefuss G, Georg Knapstein P, Koelbl H, Kelleher DK, Vaupel P (2004) The impact of treatment for genital cancer on quality of life and body image - results of a prospective longitudinal 10-year study. Gynecol Oncol 94(2):398–403PubMed
21.
go back to reference Heijkoop ST, Nout RA, Quint S, Mens JWM, Heijmen BJM, Hoogeman MS (2017) Dynamics of patient reported quality of life and symptoms in the acute phase of online adaptive external beam radiation therapy for locally advanced cervical cancer. Gynecol Oncol 147(2):439–449PubMed Heijkoop ST, Nout RA, Quint S, Mens JWM, Heijmen BJM, Hoogeman MS (2017) Dynamics of patient reported quality of life and symptoms in the acute phase of online adaptive external beam radiation therapy for locally advanced cervical cancer. Gynecol Oncol 147(2):439–449PubMed
22.
go back to reference Jiang H et al (2016) Vaginal extension improves sexual function in patients receiving laparoscopic radical hysterectomy. Gynecol Oncol 27 Jiang H et al (2016) Vaginal extension improves sexual function in patients receiving laparoscopic radical hysterectomy. Gynecol Oncol 27
23.
go back to reference Liu B, Li L, Wang M, Wei L, Li J, Zou W, Lv Y, Zhang H, Liu S (2019) Health-related quality of life in locally advanced cervical cancer patients treated with neoadjuvant therapy followed by radical surgery: a single-institutional retrospective study from a prospective database. Gynecol Oncol 154(3):583–589PubMed Liu B, Li L, Wang M, Wei L, Li J, Zou W, Lv Y, Zhang H, Liu S (2019) Health-related quality of life in locally advanced cervical cancer patients treated with neoadjuvant therapy followed by radical surgery: a single-institutional retrospective study from a prospective database. Gynecol Oncol 154(3):583–589PubMed
24.
go back to reference Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, Anchora LP, Scambia G, Ferrandina G (2013) Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis. BMC Cancer 13:127PubMedPubMedCentral Mantegna G, Petrillo M, Fuoco G, Venditti L, Terzano S, Anchora LP, Scambia G, Ferrandina G (2013) Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis. BMC Cancer 13:127PubMedPubMedCentral
25.
go back to reference Pieterse QD, Kenter GG, Maas CP, de Kroon CD, Creutzberg CL, Trimbos JBMZ, ter Kuile MM (2013) Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study. Int J Gynecol Cancer 23(9):1717–1725PubMed Pieterse QD, Kenter GG, Maas CP, de Kroon CD, Creutzberg CL, Trimbos JBMZ, ter Kuile MM (2013) Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study. Int J Gynecol Cancer 23(9):1717–1725PubMed
26.
go back to reference He H et al (2017) Laparoscopic radical surgery in early-stage cervical cancer: short-term and long-term outcomes and survival analysis. Int J Clin Exp Med 10(8):12044–12055 He H et al (2017) Laparoscopic radical surgery in early-stage cervical cancer: short-term and long-term outcomes and survival analysis. Int J Clin Exp Med 10(8):12044–12055
27.
go back to reference Barnas E et al (2012) The quality of life of women treated for cervical cancer. Eur J Oncol Nurs 16(1):59–63PubMed Barnas E et al (2012) The quality of life of women treated for cervical cancer. Eur J Oncol Nurs 16(1):59–63PubMed
28.
go back to reference Fleming ND, Ramirez PT, Soliman PT, Schmeler KM, Chisholm GB, Nick AM, Westin SN, Frumovitz M (2016) Quality of life after radical trachelectomy for early-stage cervical cancer: a 5-year prospective evaluation. Gynecol Oncol 143(3):596–603PubMedPubMedCentral Fleming ND, Ramirez PT, Soliman PT, Schmeler KM, Chisholm GB, Nick AM, Westin SN, Frumovitz M (2016) Quality of life after radical trachelectomy for early-stage cervical cancer: a 5-year prospective evaluation. Gynecol Oncol 143(3):596–603PubMedPubMedCentral
29.
go back to reference Fokdal L, Pötter R, Kirchheiner K, Lindegaard JC, Jensen NBK, Kirisits C, Chargari C, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K (2018) Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol 127(3):423–430PubMed Fokdal L, Pötter R, Kirchheiner K, Lindegaard JC, Jensen NBK, Kirisits C, Chargari C, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K (2018) Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol 127(3):423–430PubMed
30.
go back to reference Jensen NBK, Pötter R, Kirchheiner K, Fokdal L, Lindegaard JC, Kirisits C, Mazeron R, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K, EMBRACE Collaborative Group (2018) Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: physician- and patient reported outcome from the EMBRACE study. Radiother Oncol 127(3):431–439PubMed Jensen NBK, Pötter R, Kirchheiner K, Fokdal L, Lindegaard JC, Kirisits C, Mazeron R, Mahantshetty U, Jürgenliemk-Schulz IM, Segedin B, Hoskin P, Tanderup K, EMBRACE Collaborative Group (2018) Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: physician- and patient reported outcome from the EMBRACE study. Radiother Oncol 127(3):431–439PubMed
31.
go back to reference Kirchheiner K, Czajka-Pepl A, Ponocny-Seliger E, Scharbert G, Wetzel L, Nout RA, Sturdza A, Dimopoulos JC, Dörr W, Pötter R (2014) Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer with 2 fractions in 1 application under spinal/epidural anesthesia: incidence and risk factors. Int J Radiat Oncol Biol Phys 89(2):260–267PubMed Kirchheiner K, Czajka-Pepl A, Ponocny-Seliger E, Scharbert G, Wetzel L, Nout RA, Sturdza A, Dimopoulos JC, Dörr W, Pötter R (2014) Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer with 2 fractions in 1 application under spinal/epidural anesthesia: incidence and risk factors. Int J Radiat Oncol Biol Phys 89(2):260–267PubMed
32.
go back to reference Kirchheiner K, Nout RA, Czajka-Pepl A, Ponocny-Seliger E, Sturdza AE, Dimopoulos JC, Dörr W, Pötter R (2015) Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery - a mono-institutional prospective study. Gynecol Oncol 136(3):415–423PubMed Kirchheiner K, Nout RA, Czajka-Pepl A, Ponocny-Seliger E, Sturdza AE, Dimopoulos JC, Dörr W, Pötter R (2015) Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery - a mono-institutional prospective study. Gynecol Oncol 136(3):415–423PubMed
33.
go back to reference Kirchheiner K, Pötter R, Tanderup K, Lindegaard JC, Haie-Meder C, Petrič P, Mahantshetty U, Jürgenliemk-Schulz IM, Rai B, Cooper R, Dörr W, Nout RA, Lindegaard J, Tanderup K, Fokdal L, van der Steen Banasik E, Haie-Meder C, Dumas I, Chargari C, Nout RA, van Limbergen E, Petrič P, Segedin B, Hudej R, Erickson B, Hoskin P, Lowe G, Mahantshetty U, Swamidas J, Shrivastava SK, Jürgenliemk-Schulz IM, de Leeuw A, Kirchheiner K, Dörr W, Pötter R, Lutgens LCHW, Hadjiev J, Cooper R, Bownes P, Sundset M, Bruheim K, Hellebust TP, Huang F, Menon G, Villafranca E, Rai B, Oinam AS, Tan LT, Bachand F, Jacobson G, Anttila M, Pieters B (2016) Health-related quality of life in locally advanced cervical cancer patients after definitive chemoradiation therapy including image guided adaptive brachytherapy: an analysis from the EMBRACE study. Int J Radiat Oncol Biol Phys 94(5):1088–1098PubMed Kirchheiner K, Pötter R, Tanderup K, Lindegaard JC, Haie-Meder C, Petrič P, Mahantshetty U, Jürgenliemk-Schulz IM, Rai B, Cooper R, Dörr W, Nout RA, Lindegaard J, Tanderup K, Fokdal L, van der Steen Banasik E, Haie-Meder C, Dumas I, Chargari C, Nout RA, van Limbergen E, Petrič P, Segedin B, Hudej R, Erickson B, Hoskin P, Lowe G, Mahantshetty U, Swamidas J, Shrivastava SK, Jürgenliemk-Schulz IM, de Leeuw A, Kirchheiner K, Dörr W, Pötter R, Lutgens LCHW, Hadjiev J, Cooper R, Bownes P, Sundset M, Bruheim K, Hellebust TP, Huang F, Menon G, Villafranca E, Rai B, Oinam AS, Tan LT, Bachand F, Jacobson G, Anttila M, Pieters B (2016) Health-related quality of life in locally advanced cervical cancer patients after definitive chemoradiation therapy including image guided adaptive brachytherapy: an analysis from the EMBRACE study. Int J Radiat Oncol Biol Phys 94(5):1088–1098PubMed
34.
go back to reference Ljuca D, Marosevic G (2011) Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancer. Bosnian J Basic Med Sci 11(1):62–64 Ljuca D, Marosevic G (2011) Impact of chemoradiotherapy on vaginal and sexual function of patients with FIGO IIb cervical cancer. Bosnian J Basic Med Sci 11(1):62–64
35.
go back to reference Najjari Jamal D, Pötter R, Haie-Meder C, Lindegaard JC, Juergenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Wiebe E, Cooper R, Tanderup K, Kirchheiner K, EMBRACE collaborative group (2018) Physician assessed and patient reported lower limb edema after definitive radio(chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: a report from the EMBRACE study. Radiother Oncol 127(3):449–455PubMed Najjari Jamal D, Pötter R, Haie-Meder C, Lindegaard JC, Juergenliemk-Schulz IM, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Wiebe E, Cooper R, Tanderup K, Kirchheiner K, EMBRACE collaborative group (2018) Physician assessed and patient reported lower limb edema after definitive radio(chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: a report from the EMBRACE study. Radiother Oncol 127(3):449–455PubMed
36.
go back to reference Smet S, Pötter R, Haie-Meder C, Lindegaard JC, Schulz-Juergenliemk I, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van Limbergen E, Tanderup K, Kirchheiner K, EMBRACE Collaborative Group (2018) Fatigue, insomnia and hot flashes after definitive radiochemotherapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study. Radiother Oncol 127(3):440–448PubMed Smet S, Pötter R, Haie-Meder C, Lindegaard JC, Schulz-Juergenliemk I, Mahantshetty U, Segedin B, Bruheim K, Hoskin P, Rai B, Huang F, Cooper R, van Limbergen E, Tanderup K, Kirchheiner K, EMBRACE Collaborative Group (2018) Fatigue, insomnia and hot flashes after definitive radiochemotherapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: an analysis from the EMBRACE study. Radiother Oncol 127(3):440–448PubMed
37.
go back to reference Cella D, Huang HQ, Monk BJ, Wenzel L, Benda J, McMeekin DS, Cohn D, Ramondetta L, Boardman CH (2010) Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 119(3):531–537PubMedPubMedCentral Cella D, Huang HQ, Monk BJ, Wenzel L, Benda J, McMeekin DS, Cohn D, Ramondetta L, Boardman CH (2010) Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 119(3):531–537PubMedPubMedCentral
38.
go back to reference Long IHJ et al (2006) Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 100(3):537–543PubMed Long IHJ et al (2006) Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 100(3):537–543PubMed
39.
go back to reference McQuellon RP, Thaler HT, Cella D, Moore DH (2006) Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 101(2):296–304PubMed McQuellon RP, Thaler HT, Cella D, Moore DH (2006) Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 101(2):296–304PubMed
40.
go back to reference Monk BJ, Huang HQ, Cella D, Long HJ 3rd, Gynecologic Oncology Group Study (2005) Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol 23(21):4617–4625 Monk BJ, Huang HQ, Cella D, Long HJ 3rd, Gynecologic Oncology Group Study (2005) Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol Off J Am Soc Clin Oncol 23(21):4617–4625
41.
go back to reference Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22(15):3113–3119PubMed Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22(15):3113–3119PubMed
42.
go back to reference Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ III, Ramondetta LM, Landrum LM, Oaknin A, Reid TJA, Leitao MM, Method M, Michael H, Tewari KS (2015) Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 16(3):301–311PubMedPubMedCentral Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ III, Ramondetta LM, Landrum LM, Oaknin A, Reid TJA, Leitao MM, Method M, Michael H, Tewari KS (2015) Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 16(3):301–311PubMedPubMedCentral
43.
go back to reference Cocks K, King MT, Velikova G, de Castro G Jr, Martyn St-James M, Fayers PM, Brown JM (2012) Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer 48(11):1713–1721PubMed Cocks K, King MT, Velikova G, de Castro G Jr, Martyn St-James M, Fayers PM, Brown JM (2012) Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer 48(11):1713–1721PubMed
44.
go back to reference Kim JH, Park EC (2015) Impact of socioeconomic status and subjective social class on overall and health-related quality of life. BMC Public Health 15:783PubMedPubMedCentral Kim JH, Park EC (2015) Impact of socioeconomic status and subjective social class on overall and health-related quality of life. BMC Public Health 15:783PubMedPubMedCentral
45.
go back to reference van Gent MD et al (2016) Nerve-sparing radical hysterectomy versus conventional radical hysterectomy in early-stage cervical cancer. A systematic review and meta-analysis of survival and quality of life. Maturitas 94:30–38PubMed van Gent MD et al (2016) Nerve-sparing radical hysterectomy versus conventional radical hysterectomy in early-stage cervical cancer. A systematic review and meta-analysis of survival and quality of life. Maturitas 94:30–38PubMed
46.
go back to reference Xue Z, Zhu X, Teng Y (2016) Comparison of nerve-sparing radical hysterectomy and radical hysterectomy: a systematic review and meta-analysis. Cell Physiol Biochem 38(5):1841–1850PubMed Xue Z, Zhu X, Teng Y (2016) Comparison of nerve-sparing radical hysterectomy and radical hysterectomy: a systematic review and meta-analysis. Cell Physiol Biochem 38(5):1841–1850PubMed
47.
go back to reference Gubbala K, Laios A, Gallos I, Pathiraja P, Haldar K, Ind T (2014) Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis. J Ovarian Res 7(1):69PubMedPubMedCentral Gubbala K, Laios A, Gallos I, Pathiraja P, Haldar K, Ind T (2014) Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis. J Ovarian Res 7(1):69PubMedPubMedCentral
48.
go back to reference Vistad I, Fossa SD, Dahl AA (2006) A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol 102(3):563–572PubMed Vistad I, Fossa SD, Dahl AA (2006) A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol 102(3):563–572PubMed
49.
go back to reference Pfaendler KS, Wenzel L, Mechanic MB, Penner KR (2015) Cervical cancer survivorship: long-term quality of life and social support. Clin Ther 37(1):39–48PubMedPubMedCentral Pfaendler KS, Wenzel L, Mechanic MB, Penner KR (2015) Cervical cancer survivorship: long-term quality of life and social support. Clin Ther 37(1):39–48PubMedPubMedCentral
50.
go back to reference Klugel S et al (2017) Concomitant psychiatric symptoms and impaired quality of life in women with cervical cancer: a critical review. Int J Women's Health 9:795–805 Klugel S et al (2017) Concomitant psychiatric symptoms and impaired quality of life in women with cervical cancer: a critical review. Int J Women's Health 9:795–805
51.
go back to reference Ye S, Yang J, Cao D, Lang J, Shen K (2014) A systematic review of quality of life and sexual function of patients with cervical cancer after treatment. Int J Gynecol Cancer 24(7):1146–1157PubMed Ye S, Yang J, Cao D, Lang J, Shen K (2014) A systematic review of quality of life and sexual function of patients with cervical cancer after treatment. Int J Gynecol Cancer 24(7):1146–1157PubMed
52.
go back to reference Lammerink E et al (2012) Sexual functioning of cervical cancer survivors: a review with a female perspective. Int J Gynecol Cancer 22:E649 Lammerink E et al (2012) Sexual functioning of cervical cancer survivors: a review with a female perspective. Int J Gynecol Cancer 22:E649
Metadata
Title
A systematic review of the impact of contemporary treatment modalities for cervical cancer on women’s self-reported health-related quality of life
Authors
L. M. Wiltink
M. King
F. Müller
M. S. Sousa
M. Tang
A. Pendlebury
J. Pittman
N. Roberts
L. Mileshkin
R. Mercieca-Bebber
M.-A. Tait
R. Campbell
C. Rutherford
Publication date
01-10-2020
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05554-2

Other articles of this Issue 10/2020

Supportive Care in Cancer 10/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine